Early Phase 1 Hepatitis B Trial, Recruiting NCT05922306 Sponsor: Anhui Medical University Condition: Hepatitis B
Back to Hepatitis B

Early Phase 1 Hepatitis B Trial, Recruiting

NCT05922306
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 60 years old (including both ages), of any sex
  • You have tested positive for the hepatitis B surface antigen (a marker of hepatitis B infection) for more than 6 months
  • If you are already on antiviral medication for hepatitis B: you have been taking it continuously for more than 6 months, your hepatitis B surface antigen level is at or above 1500 IU/ml, and the amount of hepatitis B virus in your blood is very low (below 500 IU/ml) at the time of joining
  • If you have not yet been treated: your hepatitis B surface antigen level is above 1500 IU/ml and you meet the treatment criteria set out in the 2019 Chinese guidelines for chronic hepatitis B (confirm with trial site)
  • If you are a woman who could become pregnant, you must have a negative pregnancy test within 24 hours before your first dose

Who may not be able to join:

  • You currently have an active infection with hepatitis A, C, D, E, or HIV alongside hepatitis B
  • You are currently taking, or plan to continue taking, a medication called telbivudine
  • Your alpha-fetoprotein (a liver marker) level is above 100 ng/ml at screening, or it has not been stable for the 3 months before the trial, or a liver scan suggests a possible liver tumour (confirm with trial site)
  • You have serious liver disease that is no longer working properly, shown by any of the following: your blood clotting time is significantly prolonged, your bilirubin (a liver chemical) is too high, or you have a history of mental confusion caused by liver failure, bleeding from veins in your food pipe, or fluid build-up in your abdomen
  • You are pregnant, breastfeeding, planning to become pregnant during the study, or unwilling to use contraception
  • Your white blood cell count (a type called neutrophils) or platelet count is too low, or your kidney function marker (creatinine) is too high (confirm with trial site for exact numbers)
  • You have a history of serious mental illness, particularly severe depression, psychosis, suicide attempts, or have been hospitalised due to a psychiatric condition
  • You have a history of a disease where your immune system attacks your own body (such as lupus, rheumatoid arthritis, inflammatory bowel disease, or severe psoriasis), or you have abnormally high levels of certain immune markers in your blood
  • You have serious disease affecting your heart, lungs, kidneys, brain, or blood, or you have any other type of cancer
  • You have a history of serious epilepsy or are currently taking anti-epilepsy medications; your diabetes, high blood pressure, or thyroid condition is not well controlled; or you have a history of serious eye (retina) disease
  • You have previously had an organ transplant and still have a functioning transplanted organ (corneal or hair transplants are excepted)
  • You are allergic to interferon or any of its ingredients, or the trial doctor does not think interferon is appropriate for you
  • The trial doctor considers you unsuitable for the study for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Jiabing Li, MD, The First Affiliated Hospital of Anhui Medical University

Phone: 13956938032

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Anhui Medical University
Registry
ClinicalTrials.gov
Start date
1 July 2023
Est. completion
1 June 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

HBsAg negative conversion rate after 96 weeks of treatment; HBsAb conversion rate after 96 weeks of treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov